Figure 3 shows the additional changes in the % difference of CD8+ T cellsubsets burden by LDLT in comparison with the pretransplant immune status atvarious times in a55-year-old female recipient who underwent LDLT to treat HCV-related livercirrhosis and hepatocellular carcinoma. The gene discussed is CD8A; the disease is hepatocellular carcinoma.